Tebentafusp (IMCgp100; Immunocore) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-line treatment in patients with metastatic uveal melanoma, according to Phase 3 clinical trial results presented at the American Association for Cancer Research (AACR) Annual Meeting 2021.
In the study, 378 patients were treated with tebentafusp (n = 252) or investigator’s choice of therapy (n = 126).
In the tebentafusp group versus the investigator’s choice group, there was an estimated 1-year OS rate of 73.2% and 58.5%, respectively. Overall survival remained significant with tebentafusp when compared to investigator’s choice of therapy of pembrolizumab and dacarbazine.
“This is the first investigational therapy to demonstrate improved OS in metastatic uveal melanoma,” said Bahija Jallal, Chief Executive Officer of Immunocore, in a press release. “We believe these data demonstrate that tebentafusp has the potential to provide a meaningful difference in the treatment of metastatic uveal melanoma, a highly aggressive disease for which there is no effective standard of care.”
Read the full press release here.